Division of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet, Stockholm, Sweden.
Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden.
Sci Rep. 2018 Nov 20;8(1):17079. doi: 10.1038/s41598-018-34710-2.
Targeted antiviral immune responses to the widespread human pathogens cytomegalovirus (CMV) and Epstein-Barr virus (EBV) play a pivotal role in determining immune fitness. We show here for the first time that tumor-infiltrating B cell (TIB)- derived immunoglobulin G (IgG) from patients with pancreatic cancer or glioblastoma have unique anti-CMV/EBV immune recognition patterns compared to serum IgG. There is also great heterogeneity between patients, as well as between serum and TIB-IgG, while some viral targets elicited strongly both T-cell and IgG reactivity in tumor infiltrating T- and B-cells. These observations suggest that the anti-CMV/EBV humoral immune response in situ is highly unique and can be instrumental in developing next-generation immuno-biomarkers in addition to supplementing cellular therapy strategies for personalized cancer therapy targeting CMV or EBV in the tumor microenvironment.
针对广泛存在的人类病原体巨细胞病毒 (CMV) 和爱泼斯坦-巴尔病毒 (EBV) 的靶向抗病毒免疫反应在决定免疫适应性方面起着关键作用。我们在这里首次表明，与血清 IgG 相比，来自胰腺癌或胶质母细胞瘤患者的肿瘤浸润 B 细胞 (TIB)-衍生的免疫球蛋白 G (IgG) 具有独特的抗 CMV/EBV 免疫识别模式。患者之间以及血清和 TIB-IgG 之间也存在很大的异质性，而一些病毒靶标在肿瘤浸润的 T 细胞和 B 细胞中同时引发强烈的 T 细胞和 IgG 反应。这些观察结果表明，原位抗 CMV/EBV 体液免疫反应非常独特，可以帮助开发下一代免疫生物标志物，除了补充针对肿瘤微环境中的 CMV 或 EBV 的细胞治疗策略外，还可以用于个性化癌症治疗。
